Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|November 15, 2014
- Pharmaceutical Technology-11-15-2014
- Volume 2014 eBook
- Issue 3
Rapid Screening for Elemental Impurities using ICP-MS
Author(s)Fadi Abou-Shakra, Jonathan L. Sims
The authors describe a rapid, single-point calibration approach for ICP–MS analysis of raw materials used in drug product manufacturing.
Advertisement
The official implementation of United States Pharmacopeia (USP) <232> will require measurement of elemental impurities using inductively coupled plasma–mass spectrometry (ICP–MS). The authors describe a rapid, single-point calibration approach for ICP–MS analysis of raw materials used in drug product manufacturing.
Download Pharmaceutical Technology’s
.
Articles in this issue
almost 12 years ago
The Challenge of Finding the Unknownalmost 12 years ago
Keys to Successful Method Transferalmost 12 years ago
AQbD Adds Rigor to Method Developmentalmost 12 years ago
Validation of a Multiplex Bead-Based Assayalmost 12 years ago
Standardizing Data Managementalmost 12 years ago
Advances in Analytical TechnologyAdvertisement
Related to this article
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5